FDA Clears 2 Alzheimer’s Blood Tests as Medicare Gaps Threaten $781 Billion Dementia Burden
Updated
Updated · Medical Daily · Jun 26
FDA Clears 2 Alzheimer’s Blood Tests as Medicare Gaps Threaten $781 Billion Dementia Burden
2 articles · Updated · Medical Daily · Jun 26
Summary
Two FDA-cleared blood tests for Alzheimer’s biomarkers are now available for adults 55 and older with cognitive symptoms, replacing reliance on spinal taps and PET scans with cheaper, less invasive options.
The first test, approved in May 2025, showed 91.7% of positive results and 97.3% of negative results matched follow-up PET or spinal-fluid findings; a second test was cleared for primary care in October 2025.
Medicare still does not cover pre-symptom screening, and symptomatic patients may still face $500 to $1,000 out-of-pocket costs, limiting uptake despite lower prices than $3,000 to $6,000 PET scans.
Rural areas face the biggest access gap because many patients lack neurologists, trained primary-care doctors, and follow-up testing capacity; about 20% of cases also fall into an intermediate range needing more evaluation.
USC estimated U.S. dementia costs at $781 billion in 2025, underscoring why advocates are pushing the pending ASAP Act and broader physician training to expand early detection and treatment access.
A breakthrough Alzheimer's test exists, but many can't access it. How can the US healthcare system close this critical diagnostic gap?
With costly drugs and no cure, is knowing your Alzheimer's risk from a simple blood test a blessing or a curse?
The Alzheimer’s Blood Test Revolution: FDA Approval, Access Gaps, and the Urgent Path to Equitable Early Diagnosis (2025–2026)
Overview
The FDA’s approval of new noninvasive blood tests for Alzheimer’s disease in June 2026 marks a major breakthrough in early detection. These tests are more accessible and cost-effective than previous methods, making it easier for patients to get diagnosed sooner. Early detection is especially important now that disease-modifying treatments like Leqembi and Kisunla are available, as they can improve cognition in people with mild cognitive impairment or early-stage Alzheimer’s. This combination of better tests and effective treatments gives patients a greater chance to benefit from early intervention, representing a giant step forward in Alzheimer’s care.